- Home
- CISS vs PPBT Comparison
CISS vs PPBT Comparison
Compare CISS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | PPBT |
|---|---|---|
| Founded | 2022 | 2010 |
| Country | Greece | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2M | 1.4M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CISS | PPBT |
|---|---|---|
| Price | $0.08 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 25.8M | 25.9K |
| Earning Date | 05-19-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.41 |
| 52 Week High | $6.06 | $5.18 |
Technical Indicators
Market Signals| Indicator | CISS | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 17.56 | 51.74 |
| Support Level | N/A | $1.38 |
| Resistance Level | $0.25 | $1.85 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 0.27 | 80.98 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.